• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Quintiles seeks to refinance debt

Quintiles seeks to refinance debt

March 9, 2011
CenterWatch Staff

Quintiles, looking to take advantage of more favorable terms from banks, is seeking to refinance $1.7 billion in debt and bolster its capital in the process, according to a report in the Triangle Business Journal.

The company wants to sell about $2.4 billion in debt. It would use $1.7 billion to retire an existing debt with higher rates and use the remaining money for acquisitions, partnerships, dividend payouts and share repurchases.

The new financing, if completed, would not change the ownership structure of Quintiles, said company spokesman Phil Bridges. Private equity players TPG Capital and Bain Capital bought One Equity Partners’ majority stake in Quintiles for more than $3 billion in 2008. Among other investors in Quintiles are company founder and Chairman Dennis Gillings and companies 3i, Aisling Capital and Temasek Holdings of Singapore.

In addition to refinancing existing debt, the new credit facilities would provide Quintiles with $700 million in fresh capital the company envisions using for corporate purposes, including acquisitions and strategic alliances, or partnerships with other companies – one of Quintiles’ preferred methods of doing business.

Durham, N.C.-based Quintiles is best known for being the world’s largest provider of clinical trials services, but it also enters into a variety of partnerships with pharmaceutical and other companies in various areas of drug development and sales. For example, Quintiles will provide sales teams for drug makers looking to move product.

Bridges could not identify specific acquisition or partnership targets but confirmed that Asia remains a focus for Quintiles, which has 1,500 employees in the Triangle and more than 20,000 worldwide.

“Asia is definitely a continued focus,” Bridges said. “It is a growing area in terms of population, spending on health care and the clinical trials market.”

Speculation has been rife about Quintiles executing an initial public offering in the near future as the company’s private equity owners seek a return on investment. The fresh capital provided by the debt refinancing would seem to address some of those concerns and possibly push back an IPO. “There are no (IPO) plans at this time,” Bridges said.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing